drugset / Trial / NCT04162327
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI315, a HER2/PD-1 bi-specific antibody in patients with advanced solid tumors
Timeline
- Start
- 2019-11-26
- Primary completion
- 2022-01-27
- Completion
- 2023-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI315 | Unknown | — | — |
Indications
No indication recorded.